SCHEMBL25755058

SCHEMBL25755058

COc1ccc(NC(=O)c2cnc(C(F)(F)F)[nH]2)cc1S(=O)(=O)Nc1ccc(C)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.52
SMN1; SMN2 Q16637 5/20 0.52
HPGD P15428 3/20 0.52
HDAC1 Q13547 1/20 0.52
HDAC8 Q9BY41 1/20 0.52
HDAC6 Q9UBN7 1/20 0.52
GAA P10253 3/20 0.51
HTT P42858 1/20 0.51
MAPT P10636 4/20 0.49
POLB P06746 3/20 0.49
KMT2A Q03164 4/20 0.49
MEN1 O00255 3/20 0.48
ALDH1A1 P00352 1/20 0.48
ALOX12 P18054 1/20 0.48
CRHBP P24387 1/20 0.48
CRHR2 Q13324 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.46
RECQL P46063 1/20 0.46
ALPL P05186 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23846318 0.93 LMNA (0.52) LMNASMN1; SMN2HPGDHDAC1HDAC8
SCHEMBL25755054 0.93 MAPT (0.52) LMNASMN1; SMN2HPGDGAAMAPT
SCHEMBL25755022 0.92 KMT2A (0.59) LMNASMN1; SMN2HPGDHDAC1HDAC8
SCHEMBL25755134 0.90 LMNA (0.50) LMNASMN1; SMN2HPGDGAAMAPT
SCHEMBL23846572 0.88 IDH1 (0.44) LMNASMN1; SMN2HPGDHTTMAPT
SCHEMBL25755065 0.88 MAPT (0.53) LMNASMN1; SMN2HPGDGAAHTT
SCHEMBL23846402 0.87 ALPL (0.49) LMNASMN1; SMN2HPGDGAAMAPT
SCHEMBL25755128 0.86 MAPT (0.51) LMNASMN1; SMN2HPGDGAAHTT
SCHEMBL25757152 0.86 IDH1 (0.48) LMNASMN1; SMN2HPGDGAAHTT
SCHEMBL25757154 0.82 MEN1 (0.52) LMNASMN1; SMN2HPGDGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, TP53BP1 LMNA 3435/4885SMN1; SMN2 405/4885HPGD 2112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.